In the packed oncolytic virus space, a German biotech with a unique approach makes investors reach deeper into their wallets

When Abalos Therapeutics closed its $12 million Series A round two years ago, the company was essentially “two guys, a key and one room …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In the packed on­colyt­ic virus space, a Ger­man biotech with a unique ap­proach makes in­vestors reach deep­er in­to their wal­lets